Current guidelines focus on risk assessment and cardiovascular disease (CVD) risk reduction through lipid-lowering therapies. Statin medications are proven first-line medications; however, other evidence-based agents are available as add-on therapy to statins to reduce CVD events. The indications for statins, PCSK9 inhibitors, and other lipid-lowering therapies with an emphasis on older adult patients, are discussed.

Continuing Education Instructions and Disclosure Information

Contact hours available until 3/29/21.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Conferences Committee Disclosures:
Michael Koronkowski discloses a role as a consultant for the following: OptumRx, Inc., P&T advisor; HRSA-GWEP, co-investigator; White Crane Wellness Center, Senior Programs.

There are no other disclosures to declare.

Speakers Conflict of Interest Disclosure:
Speakers: Lynne Braun discloses that she receives a royalty from UptoDate as an author.

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
This session is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Gerontological Advanced Practice Nurses Association (GAPNA).

Anthony J. Jannetti, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Anthony J. Jannetti, Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP5387.

Learning Outcome:
After completing this learning activity, the participant will discuss risk management, guideline recommendations, and patient-centered approaches for lipid-lowering therapies for patients at intermediate or high-risk for cardiovascular disease events.

Products